### 1 Title page

#### 2

# Temporal trajectories of COVID-19 symptoms in adults with 22 months follow-up in a prospective cohort study in Norway

5 6

### 7 Authors` names

- 8 Merete Ellingjord-Dale\* (0000-0001-9294-2510), Anders Nygaard\* (0000-0003-1922-0751),
- 9 Nathalie C Støer (0000-0001-8994-9332), Ragnhild Bø (), Nils Inge Landrø (0000-0003-0354-
- 10 5148), Sonja Hjellegjerde Brunvoll (0000-0003-0917-9898), Mette Istre (0000-0001-5674-
- 11 3522), Karl Trygve Kalleberg(0000-0003-4968-2295), John Arne Dahl (0000-0002-4375-2697),
- 12 Linda Geng (0000-0002-9891-5705), Tsilidis, Kostas (0000-0001-5868-4984), Riboli, Elio
- 13 (0000-0001-6795-6080), Giske Ursin (0000-0002-0835-9507), Arne Vasli Lund Søraas (0000-
- 14 0003-1622-591X)
- 15 \*Contributed equally
- 16

### 17 Address for each author

- 18 Oslo University Hospital, Department of Microbiology, PO Box 4950 Nydalen,
- 19 Oslo, Norway, Merete Ellingjord-Dale, postdoc Oslo University Hospital,
- 20 Department of Microbiology, PO Box 4950 Nydalen, Oslo, Norway, Anders
- Nygaard, postdoc Cancer Registry of Norway, Research Department, 0379 Oslo,
- 22 Norway, Nathalie C Støer, statistician University of Oslo, Department of
- 23 Psychology, 0373 Oslo, Norway, Ragnhild Bø, postdoc University of Oslo,
- 24 Department of Psychology, 0373 Oslo, Norway, Nils Inge Landrø, professor Oslo

25	University Hospital, Department of Microbiology, PO Box 4950 Nydalen, Oslo,
26	Norway, Sonja Hjellegjerde Brunvoll, postdoc Oslo University Hospital,
27	Department of Microbiology, PO Box 4950 Nydalen, Oslo, Norway, Mette Istre,
28	molecular biologist Age Labs AS, 0373 Oslo, Norway, Karl Trygve Kalleberg,
29	CEO Oslo University Hospital, Department of Microbiology, PO Box 4950
30	Nydalen, Oslo, Norway, John Arne Dahl, researcher Department of Medicine,
31	Stanford University School of Medicine, Stanford, CA 94305, USA, Linda Geng,
32	researcher Imperial College London, School of Public Health, Department of
33	Epidemiology and Biostatistics, London SW7 2AZ, UK, University of Ioannina
34	School of Medicine, Department of Hygiene and Epidemiology, Ioannina, Greece,
35	Kostas Tsilidis, professor Imperial College London, School of Public Health,
36	Department of Epidemiology and Biostatistics, London SW7 2AZ, UK, University
37	of Ioannina School of Medicine, Department of Hygiene and Epidemiology,
38	Ioannina, Greece, Elio Riboli, professor Cancer Registry of Norway, Oslo,
39	Norway, University of Oslo, Institute of Basic Medical Sciences, Department of
40	Nutrition, 0373 Oslo, Norway, University of Southern California, Department of
41	Preventive Medicine, Los Angeles, CA, USA, Giske Ursin, professor Department
42	of Microbiology, Oslo University Hospital, PO Box 4950 Nydalen, 0424 Oslo,
43	Norway. Phone: +47 90652904. E-mail: arvsoe@ous-hf.no, Arne Søraas,
44	researcher

- 46 Corresponding author: Arne Søraas, Department of Microbiology, Oslo University
- 47 Hospital, PO Box 4950 Nydalen, 0424 Oslo, Norway. Phone: +47 90652904. E-
- 48 mail: <u>arne@meg.no</u> and <u>arvsoe@ous-hf.no</u>, researcher

# 50 What is already known of this topic

51	٠	Cognitive difficulties and physical symptoms have been reported after infections with the
52		SARS-CoV-2 virus, but lack of studies with data before and after infections have sparked
53		a global debate regarding severity and duration of these symptoms.
54	•	Post acute viral syndromes have been described after many different infections, but it is
55		unknown whether the symptoms of "long-COVID" or Post Acute Sequela after COVID-
56		19 (PASC) are specific to the SARS-CoV-2 or not.
57		
58	What	this study adds
59	•	We found a significant and long-term increase in cognitive symptoms, anosmia and
60		dysgeusia, dyspnoea, fatigue, and self-assessed worsening of overall health after a
61		positive (COVID-19) but not a negative (indication of another infection) SARS-CoV-2
62		test.
63	•	To our knowledge, this is the first large cohort study to report the trajectories of both
64		cognitive and physical symptoms from before and up to 22 months after a positive
65		SARS-CoV-2 test, compared to SARS-CoV-2 negative controls.
66		

# 68 Abstract

#### 69 **Objectives**

- 70 We aimed to describe the trajectories of cognitive and physical symptoms before, during, and
- after a positive- or negative SARS-CoV-2 test and in untested controls.

#### 72 Design

73 A prospective cohort study.

### 74 Setting

75 Norway, 27 March 2020 to 6 July 2022

#### 76 **Participants**

- A total of 146 065 volunteers were recruited. Of these, 120 605 participants (mean age 49 (SD
- 13.7), 69% female), were initially untested for the SARS-CoV-2 virus, completed one or more
- 79 follow-up questionnaires (response rates 72-90%) and were included for analysis. After 22
- 80 months of follow-up, 15 737 participants had a positive SARS-CoV-2 test, 67 305 a negative
- 81 test, and 37 563 were still untested.

#### 82 Main outcome measures

- 83 We assessed reported symptoms the past three weeks of memory or concentration problems,
- 84 anosmia and dysgeusia, dyspnoea, fatigue, fever, headache, cough, muscular pain, nasal
- symptoms, sore throat and abdominal pain at baseline and through four follow-up questionnaires.
- In addition, overall health compared to a year before was measured with a five-point scale and

- 87 memory problems were measured using the Everyday Memory Questionnaire-13 at two88 timepoints.
- 89 The exposure, SARS-CoV-2 test status (positive, negative or untested), was obtained from a
- 90 mandatory national registry or from self-report, and data were analysed using mixed model
- 91 logistic regression.

#### 92 **Results**

- 93 A positive SARS-CoV-2-test was associated with the following persistent symptoms, compared
- 94 with participants with a negative test (1-3 months after a negative test); memory problems (3 to 6
- 95 months after a positive test: adjusted odds ratio (OR) 9.1, 95% confidence interval (CI) 7.5 to
- 96 10.9; 12 to 18 months: OR 7.8, CI 5.7 to 10.8), concentration problems (3 to 6 months: OR 6.1,
- 97 CI 4.8 to 6.5; 12 to 18 months: OR 5.3, CI 3.9 to 7.1), anosmia and dysgeusia, dyspnoea and
- 98 fatigue as well as self-assessed worsening of overall health.

#### 99 **Conclusion**

- 100 A positive SARS-CoV-2 test was associated with new onset memory- and concentration
- 101 problems, anosmia and dysgeusia, dyspnoea and fatigue as well as self-assessed worsening of
- 102 overall health, which persisted for the length of the follow-up of 22 months, even when
- 103 correcting for symptoms before COVID-19 and compared to symptoms in negative controls.
- 104 **Trial registration**
- 105 ClinicalTrials ID: NCT04320732

106

## 108 Introduction

109 The World Health Organization (WHO) has reported more than 770 million COVID-19 cases,

- including around 6.9 million deaths globally, as of August 25, 2023.<sup>1</sup> It has been estimated that
- 111 more than 65 million individuals around the world suffer from post-acute sequelae of severe
- acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, often termed "long-
- 113 COVID".<sup>2</sup> The definition of the phases of COVID-19 disease varies across studies.<sup>3-8</sup> An acute
- 114 phase 0-1 month after diagnosis, followed by a post-acute phase 1-3 months, and a post-COVID-
- 115 19 phase >3 months have been described.<sup>4</sup> The WHO's description of the time frame for long-
- 116 COVID coincides with the post-COVID-19 phase.<sup>7</sup>
- 117 Previous studies have reported a range of potential long-COVID symptoms such as anosmia and
- dysgeusia, fatigue, headache, muscle pain, abdominal pain, cough, dyspnoea, hair loss, and
- 119 cognitive symptoms.<sup>2,9-23</sup> However, most of these studies lacked relevant control groups, data on
- symptoms before COVID-19, and a long follow-up time. We initiated a large prospective cohort
- 121 study in which we examined the temporal trajectories of symptoms in SARS-CoV-2-positive, -
- negative, and -untested participants, with a high response rate and a follow-up time of up to 22
- 123 months after the test date.

# 124 Methods

#### 125 Study population

The Norwegian COVID-19 Cohort Study is a population-based, open cohort study of adult
participants (aged 18-96 years) from Norway. From March 27, 2020, participants were recruited
through social media, invitations, and nationwide media coverage. Participants completed a
baseline questionnaire at inclusion and were invited to regular follow-up questionnaires. All

participants had a Norwegian identification number and electronic access to the secure nationaldigital governmental identification service.

Between March 27, 2020, to April 15, 2021, a total of 146 065 participants completed the

baseline questionnaire (99 % before June 30, 2020). Of these, 127 798 participants were untested

at baseline according to the mandatory Surveillance System for Communicable Diseases (MSIS)

registry and confirmed this through self-report. We excluded 7193 participants who did not

136 complete any follow-up questionnaires.

137 Our final study population of 120 605 had completed a baseline questionnaire and at least one

138 follow-up questionnaire before July 6, 2022. The response rates for the first (May 2020), second

139 (July 2020), third (November 2020), and fourth follow-up (December 2021) questionnaires were

140 79.3%, 84.2%, 80.4%, and 72.1%, respectively (Supplementary eFigure 1).

141 In a substudy between the 3<sup>rd</sup> and 4<sup>th</sup> follow-ups (July 2021), 6279 participants (all SARS-CoV-

142 2-positive participants, and randomly selected negative and untested participants) were invited

143 for an extra questionnaire (89.9% responded) (Supplementary eMethods 1). To assess the impact

144 of non-response on our overall study, a random subset of these (n=2090) received telephone

reminders if unresponsive electronically ("phone cohort"), with a 97% response rate in that

146 group.

147 In another add-on study, from October 2020 to December 2021, 998 blood samples from 966

148 unvaccinated participants were collected and analyzed for SARS-CoV-2 antibodies

149 (Supplementary eMethods 2).

150 The study was approved by the Norwegian Regional Committee for Research Ethics (REK

151 124170), and all participants submitted electronic informed consent forms. The study is

registered in ClinicalTrials (<u>https://clinicaltrials.gov;</u> ID: NCT04320732), and reported according
to the STROBE guidelines for cohort studies.

#### 154 Assessment of exposure

155 The exposure, SARS-CoV-2 status, was obtained through linkage of the participant's personal

identification numbers with the MSIS registry or self-report. COVID-19 became a compulsory

reportable disease to MSIS on January 31, 2020. SARS-CoV-2 tests were done by a

158 nasopharyngeal and/or oropharyngeal swab test and detected using real-time polymerase chain

reaction (rt-PCR) in any accredited Norwegian clinical microbiology laboratory. From early in

160 January, 2022, self-tests became increasingly available and PCR tests no longer mandated.

161 SARS-CoV-2 status were therefore increasingly based on self-report the in the last months of the

study. Participants could change their exposure status during the study period. We considered a

163 participant untested from inclusion until the date of a SARS-CoV-2 test (positive or negative). If

the first test was negative, a participant would be considered negative until the date of a later

165 positive test. A participant with only negative tests was considered SARS-CoV-2-negative

166 throughout the follow-up.

167 Community testing for SARS-CoV-2 status was free of charge and after the initial few months of

the pandemic widely available and strongly encouraged. Testing for international travel was

done at private facilities and required a fee and results were reported to MSIS like all other tests.

170 Testing criteria changed during the study period and is described in Supplementary eFigure 2.

171 From January 24, 2022, a PCR test was no longer routinely offered after a positive self-test.

172

173

Outcome measures were self-reported symptoms assessed through electronic follow-up

questionnaires (Supplementary eMethods 3). Questionnaires were designed using existing

knowledge about COVID-19 symptoms and the International Severe Acute Respiratory and

Emerging Infection Consortium forms.<sup>24</sup> For each questionnaire, participants were asked to

#### 174 Assessment and definition of endpoints

175

176

177

178

179	check off symptoms they had experienced the past 3 weeks.
180	In the second follow-up questionnaire, a health transition question ("Compared to a year ago, or
181	before you had COVID-19, how will you describe your health?") with a 5-point Likert scale (the
182	variable was dichotomized in the analyses), from the 36-Item Short Form Survey was added. <sup>25</sup>
183	As several participants reported memory problems in the free-text fields in the second follow-up
184	questionnaire, questions on memory- and concentration were added to the third and fourth
185	follow-up questionnaires and in the substudy between these questionnaires. To assess memory-
186	and concentration problems, the Behaviour Rating Inventory of Executive Functions-adult
187	version (BRIEF-A) <sup>26</sup> was included in the substudy, while the 13-item Everyday Memory
188	Questionnaire-revised version (EMQ-R) <sup>27</sup> was included in the substudy and fourth follow-up.

#### **189** Statistical analyses

To investigate the temporal trajectory of symptoms after COVID-19, we examined the combined effect of SARS-CoV-2 status (untested, negative, or positive) and time since a SARS-CoV-2 test (0-1, 1-3,3-6, 6-12, 12-18 and >18 months) on symptoms. Time since test was defined as the time since the first positive or negative test, or the time since baseline (for the untested). We included information from all questionnaires, and used mixed-effect logistic regression calculating odds ratios (ORs) with 95% confidence intervals (CIs) of each symptom associated

with SARS-CoV-2 status and time since test (eMethods 4). We compared symptoms of SARSCoV-2-positive and untested participants with SARS-CoV-2-negative participants at one fixed
time point, 1-3 months after their first negative test. We also compared the symptoms of SARSCoV-2-positive and untested participants at each time point with the SARS-CoV-2-negative
participants.

Analyses were adjusted for potential confounders: age (10-year categories), gender (men,

women), body mass index (BMI,<25 kg/  $m^2$ >25kg/  $m^2$ , missing), annual household income level

203 (< 299 999, 300 000-599 999, 600 000-100 0000, >1 000 000 NOK, missing), smoking status

204 (never, former, current, missing), underlying medical condition (no, yes, missing), and symptom

status for each symptom at baseline (no, yes, missing) or at the first questionnaire asking about

the symptom, but before the outcome symptom.

To illustrate the trajectories of symptoms before, during, and after a positive or negative test, we calculated the unadjusted moving average (with 95% CI) prevalence of symptoms for each exposure group (using the SARS-CoV-2-status at the last follow-up) over the whole study period (supplementary eMethods 5).

211 We performed the following sensitivity analyses and only including; participants with pre-

omicron-variants, those who completed all questionnaires (not including the substudy), non-

213 hospitalized participants, and participants with self-reported SARS-CoV-2 status.

In the substudy and fourth follow-up, we used multivariate analysis of variance to test for

215 differences in subscales of BRIEF-A by SARS-CoV-2 status, and analysis of variance

216 (ANCOVA) to test for differences by SARS-CoV-2 status on EMQ-R, controlling for age and

sex. Pairwise-comparisons between SARS-CoV-2 status (untested, negative and positive) were

- 218 Bonferroni corrected. We used ANCOVA to investigate the difference in change in EMQ-R
- between those who converted to positive and those who remained negative/untested. Point-serial
- 220 correlations between EMQ-R and BRIEF-A subscales and self-reported memory- and
- concentration problems were investigated (supplementary eTable 1).
- 222 To examine the effect of non-response bias, we conducted a sensitivity analysis in randomly
- selected participants invited to the substudy (n=2090). The non-responders were contacted by
- telephone (n = 343; 56 untested, 237 negative, and 50 positive) and were compared with those
- who had already responded through electronic reminders (n = 1692).
- Analyses were performed using Stata (Stata Statistical Software, release 16 and 17, Stata Corp.,
- 227 College Station, TX), R (version 4.2.2), and SPSS 27 (IBM).

#### 228 **Patient and Public Involvement statement**

229 We have involved patients in the Norwegian Corona Cohort since the spring of 2020. Our focus

- 230 on persisting cognitive symptoms were initiated after reports of such symptoms by a patient
- representative which led to the inclusion of relevant questions in the following questionnaires.
- 232 The study has had a two-way communication with our participants through newsletters and free-
- text-fields in the questionnaires. We have regular meetings with patients and the patient
- 234 organization Norwegian Covid Association.

# 235 **Results**

#### 236 **Participants and follow-up**

- 237 Of 120 605 participants, 15 737 were SARS-CoV-2-positive (58% from MSIS and 42% self-
- report), 67 305 negative, and 37 563 untested at the end of follow-up (July 6, 2022;

Supplementary eFigure 1). The follow-up varied between the groups and 710 SARS-CoV-2
positive, 35 309 negative, and 18 997 untested participants had >12 months follow-up after the
test (Table 1). In total, 530 200 questionnaires were included in the analyses. Of the participants,
69% were women, 41% had a per household income/ year >1 000 000 NOK (about US\$ 100
000), and the mean age was 49 years (SD = 13.7 years). SARS-CoV-2-positive were younger,
had a higher income, a lower BMI, and fewer underlying medical conditions, and were less
likely to be current smokers compared with negative and untested participants.

### 246 Symptoms among SARS-CoV-2-positive participants

The temporal trajectory of each symptom differed by SARS-CoV-2 status (Unadjusted: Figure 1 247 and Supplementary eFigure 3, and adjusted: Table 2, Supplementary eTables 2 and 3). When 248 comparing SARS-CoV-2-positive participants with negative participants (1-3 months after a 249 negative test), there were several persistent symptoms. The strongest findings in the adjusted 250 251 analyses were memory problems (3-6 months: adjusted odds ratio (OR) = 9.1, 95% confidence 252 interval (CI) = 7.5-10.9; 6-12 months: OR = 13.3, CI = 10.7-16.6; 12-18 months: OR = 7.8, CI = 253 5.7-10.8; >18 months: OR = 9.96, CI = 4.3-23.0), concentration problems (3-6 months: OR = 254 5.7, CI = 4.9-6.7; 6-12 months: OR = 7.5, CI = 6.1-9.1; 12-18 months: OR = 5.3, CI = 3.9-7.1; >18 months: OR = 4.9, CI = 2.1-11.1), and anosmia and dysgeusia (3-6 months: OR = 5.2, 95% 255 256 CI = 4.4-6.2, 6-12 months: OR = 8.9, CI = 7.2-11;12-18 months; OR = 5.5, CI = 4.0-7.5; >18 257 months: OR = 5.3, CI = 2.4-2.1) (Table 2). Self-assessed worsening of overall health was also 258 significantly higher among the SARS-CoV-2-positive participants, with the highest risk being at 259 18 months (OR = 3.7, CI = 2.0-6.8). The risk of reporting dyspnoea and fatigue was higher for 260 the positive than negative participants, but the risk attenuated over time. SARS-CoV-2 positive 261 participants were equally or less likely to report fever, headache, cough, muscular pain, nasal

symptoms, sore throat, and abdominal pain late in follow-up compared to the negative

263 participants (Supplementary eTable 2).

#### 264 Symptoms among SARS-CoV-2-negative and untested participants

Eighty percent of participants with a negative test reported at least one symptom indicating an

infection in the three-week period around testing (data not shown). At later follow-up periods,

267 SARS-CoV-2-negative participants had a higher risk of reporting symptoms compared to 1-3

months after the negative test. Memory problems (3-6 months: OR = 1.3, CI = 1.2-1.5; >18

269 months: OR = 2.0, CI = 1.7-2.3), fever (3-6 months: OR = 1.2, CI = 1.00-1.4; >18 months: OR = 1.2, CI = 1.00-1.4; >18 months: OR = 1.2, CI = 1.00-1.4; >18 months: OR = 1.2, O

- 270 2.1, CI = 1.8-2.3), and cough (3-6 months: OR = 1.0, CI = 0.94-1.1; >18 months: OR = 1.5, CI =
- 1.4-1.7) were increasingly reported over time among negative participants (Table 2 and
- 272 Supplementary eTable 2). We therefore conducted analyses comparing SARS-CoV-2-positive
- with negative participants at each time point (Supplementary eTable 3). Untested participants
- were less likely to report symptoms compared to SARS-CoV-2-negative participants.

#### 275 **Disease severity and persisting symptoms**

A longer time bedridden with COVID-19 was associated with an increased risk of persisting

- symptoms, except for sore throat and nasal symptoms. The strongest association in the adjusted
- analyses was seen for memory problems (bedridden 1-6 days: OR = 2.1, CI = 2.0-2.7, bedridden
- 279 7-13 days: OR = 5.3, CI = 4.3-6.6, and bedridden >=14 days: OR 9.1, CI 6.5-12.8, compared to
- not being bedridden during COVID-19) (Supplementary eMethods 6, and eTable 4).

#### 281 Sensitivity analyses

When excluding participants with SARS-CoV-2 Omicron variants (BA.1 and BA.2), the results
were consistent (eFigure 4), but the ORs for memory problems, concentration problems, and

284	anosmia and dysgeusia 3-6 months after the positive test were higher compared to when all cases
285	were included (data not shown). In other sensitivity analyses, we included only those who
286	completed all questionnaires, excluded hospitalized COVID-19 participants (4%), and
287	participants with self-reported SARS-CoV-2 status, and the results remained largely unchanged
288	(data not shown). In one sensitivity analysis, only participants answering questionnaires both
289	before and after a positive or negative SARS-CoV-2 test were included and the results were
290	similar to when all questionnaires were included (data not shown).

#### 291 Validated questionnaires on cognitive function, phone cohort and serology

292 Compared to SARS-CoV-2 negative participants, positive participants reported more functional

memory problems on the EMQ-R (Supplementary eFigure 5; substudy: Mean difference = 0.262,

294 CI = 0.204 - 0.321; fourth follow-up: Mean difference = 0.329, CI = 0.298 - 0.394), and poorer

working memory function (BRIEF-A subscale, Supplementary eFigure 6; Mean difference =

0.620, CI= 0.346-0.894). There were no significant differences on the other BRIEF-A subscales.

297 With regard to change in EMQ-R, those who converted to positive at fourth follow-up had larger

changes (n = 223; M=.124, SD = .63) than those who remained negative or untested (n = 2489;

299 M=.029, SD = .449), mean difference = .096, CI = .031, .160, p = .004). We performed

300 correlation tests between EMQ-R/BRIEF-A Working memory subscale, and self-reported

memory- and concentration problems and found small (Pearson's r from 0.26 to 0.40), but

302 significant correlations between these measurements (Supplementary eTable 1).

303 In the subgroup of participants contacted by telephone (n=343), a lower proportion, reported

304 symptoms compared with those who responded through electronic invitations. This difference

305 was more pronounced among positive than among negative participants (Supplementary eFigure

306 7).

In the add-on serology study of 966 participants, blood samples were analysed for SARS-CoV-2
antibodies, 3 (0.3%) were positive but classified as negative or untested at the time of sampling
(Supplementary eMethods 2).

# 310 **Discussion**

318

functional and working memory.

In this prospective cohort study, we have analysed the temporal trajectory of 14 symptoms (13 symptoms and self-assessed worsening of overall health) before, during and after a positive or negative SARS-CoV-2 test. When comparing SARS-CoV-2-positive participants with negative participants, persistent symptoms were memory- and concentration problems, anosmia and dysgeusia, dyspnoea, fatigue, and self-assessed worsening of overall health. The cognitive symptoms and self-assessed worsening of overall health did not attenuate over time. SARS-CoV-2 positive participants also scored worse than negative participants in validated tests of

319 Our finding of memory- and concentration problems as long-COVID symptoms is in line with a report by the WHO<sup>28</sup> and several studies.<sup>9,10,12-16,29</sup> However, the results elaborates this 320 association with several important findings. Firstly, the association between COVID-19 and 321 memory- and concentration problems was strong, and after the acute phase – as strong as the 322 323 association between COVID-19 and anosmia and dysgeusia. Secondly, memory- and concentration problems increased in the 0-6 months interval after a positive SARS-CoV-2 test 324 325 and persisted throughout the follow-up time up to 22 months. In contrast, the other symptoms 326 peaked in prevalence during the acute phase and thereafter exhibited a downwards trend. To our knowledge, this has not previously been reported and may indicate that the pathophysiological 327 328 processes underlying the cognitive symptoms may differ from other long-COVID symptoms.

329 The strong association and a temporal trajectory specific for cognitive symptoms warrants330 further research.

331	Several studies have examined the neuropathological effects of the SARS-CoV-2 virus and
332	possible mechanisms associated with COVID-19.30-33 Brain imaging studies have reported a
333	greater reduction of grey matter <sup>30</sup> and an increase of white matter lesions after COVID-19 <sup>31</sup> ,
334	whereas an autopsy study found the virus persisting in the brain of COVID-19 patients. <sup>32</sup>
335	Another study has suggested that synaptic signalling of neurons may expand after COVID-19
336	disease <sup>33</sup> and could be linked to neurodegenerative and psychiatric disorders. <sup>34-36</sup> The SARS-
337	CoV-2-positive participants' scores on BRIEF-A and EMQ-R in the current study indicate that
338	most participants reporting memory- and concentration problems had mild cognitive
339	impairments. However, even slight cognitive impairments can have profound effects on
340	everyday functioning because working memory supports decision-making, navigation, and
341	problem-solving, and it helps keep track of conversations. <sup>37</sup> The fact that cognitive symptoms are
342	persistent, and most of the population have been, or will be, infected by the SARS-CoV-2 virus,
343	makes it crucial that further research focuses on the pathophysiology, and treatment (including
344	whether immediate treatment upon symptom debut are effective) of these symptoms. <sup>38</sup>
345	Our findings are consistent with a large recent cohort study examining cognitive trajectories in
346	older adults <sup>29</sup> . They asked about history of COVID-19 in the year before each questionnaire, and
347	a decline in cognition was observed after COVID-19 compared to pre-pandemic year.
348	A recently published report from the Lifelines Study analysed 23 somatic (not cognitive) self-
349	reported symptoms from 76 000 participants, 90-150 days after COVID-19, and had a matched
350	non-infected control group. <sup>2</sup> Our findings on anosmia and dysgeusia, dyspnoea, and fatigue are
351	consistent with their findings. However, we included a control group with negative tests (80% of

352	the participants with a negative test reported $\geq 1$ symptoms of an infection at the time of testing),
353	allowing us to identify symptoms specific to the SARS-CoV-2 virus compared to other
354	infections. This could be one of the reasons why the current study did not find any association
355	between COVID-19 and persisting fever, headache, cough, nasal symptoms, sore throat, or
356	abdominal pain when we compared SARS-CoV-2 positive and negative participants. We
357	observed an upwards trend in symptoms associated with upper respiratory tract infections
358	(URTI) among the SARS-CoV-2-negative participants over time. This was probably because
359	lockdown measures were gradually relaxed throughout the pandemic.
360	Our findings are also consistent with findings from a large cohort study following 138 818
361	SARS-CoV-2-positive and 5 985 227 controls from the US Department of Veterans Affairs. <sup>39</sup> In
362	that study, diagnoses were tracked up to two years after COVID-19 and the risk of 27 of 79
363	diagnoses were still elevated 2 years after COVID-19 compared to non-infected controls.
364	Furthermore, in a cross-sectional study (EPILOC) on 50 457 SARS-CoV-2 positive participants
365	reported that fatigue, neurocognitive impairment, dyspnoea, anosmia, and dysgeusia persisted 6-
366	12 months after the SARS-CoV-2 infection. <sup>40</sup>
367	The current study is a large prospective cohort with a long follow-up period, and multiple
368	follow-up questionnaires, including before disease, with a high response rate. The study included
369	a SARS-CoV-2-negative control group, making it possible to capture differences between
370	COVID-19 and other infections. The SARS-CoV-2 status was obtained from accredited
371	laboratories through MSIS which covers nearly 100% of the population. Another strength is the

373 Participants were asked to report symptoms experienced in the last three weeks in each

questionnaire, and we cannot rule out recall bias. Knowledge of exposure status and media

reports on long-COVID symptoms may have biased the self-reported outcome assessment 375 376 leading to exaggerated ORs for known long-COVID symptoms, at least later in the follow-up 377 period once these became common knowledge ("nocebo effect"). Since data on the symptoms were reported as a three-week symptom prevalence, participants reporting "no symptoms" could 378 still have had symptoms at some point in time. Our coverage of long-COVID symptoms is not 379 380 exhaustive, and symptoms not known to be related to acute or long-COVID early in the pandemic are not included (i.e., orthostatic intolerance, dysautonomia, palpitations, light-381 382 headedness, or post-exertional malaise). There may be testing bias in the comparison between 383 the tested and untested participants. For this reason, we provided results both on positive, negative and untested participants. 384 385 We cannot rule out non-differential measurement error caused by false negative SARS-CoV-2 386 tests. However, in our add-on study with serological screening, we only identified 3 out of 966 387 (0.3%) unacknowledged cases of COVID-19. In the sensitivity analysis of the substudy, we 388 contacted a subgroup of participants by telephone, and found that a lower proportion reported 389 symptoms compared with those who responded through electronic invitations. This difference 390 was more pronounced among SARS-CoV-2-positive, than among negative participants and 391 could have led to an overestimation of the effect of COVID-19 on symptoms. We did not adjust for multiple testing in the statistical analyses. Nevertheless, the clinical relevance of the actual 392 differences and sizes is the most essential. 393

394

The generalizability of our findings is limited by our cohort composition, which has lower proportions of males, non-white ethnic groups, individuals with lower income, older individuals and no children compared to the Norwegian population. Persistent long-COVID symptoms

- lasting up to 22 months were memory- and concentration problems, anosmia and dysgeusia,
- dyspnoea, fatigue and self-assessed worsening of overall health. We could not establish an
- 400 association between COVID-19 and persisting fever, headache, cough, nasal symptoms, sore
- 401 throat, or abdominal pain suggesting that the role of previous COVID-19 infections in patients
- 402 presenting with such symptoms may not be important.
- 403 The core long-COVID-19 symptoms may have a long-lasting negative impact on peoples' lives
- and should be in focus in further research and in long-COVID rehabilitation.

405	<b>Table 1.</b> Frequency distribution and mean values of covariates by SARS-CoV-2 status at fourth follow-up <sup>a</sup> ( $n = 120$ )
406	605).

	SARS-CoV-2 positive <sup>a</sup>	SARS-CoV-2-negative	<b>Untested</b> <sup>b</sup>						
	(n = 15737)	$(n = 67 \ 305)$	(n = 37563)						
Characteristics									
	Median (IQR) <sup>c</sup>								
Time since test (days) <sup>d</sup>	55 (15-106)	419 (292-501)	637 (633-669)						
		Mean (SD)							
Age (years)	46 (12.1)	48 (13.3)	51 (14.7)						
		n (%)							
18-29	1298 (8)	5081 (8)	3150 (8)						
30-39	3956 (25)	14 331 (21)	6490 (17)						
40-49	4899 (31)	17 108 (26)	7769 (21)						
50-59	3429 (22)	16 164 (24)	8765 (24)						
60-69	1608 (10)	10 325 (15)	7166 (19)						
70+	547 (4)	4296 (6)	4223 (11)						
Sex									
Men	4287 (27)	18 879 (28)	13 750 (37)						
Women	11 450 (73)	48 426 (72)	23 813 (63)						
Income (NOK per household									
and year)									
< 299 999	477 (3)	2422 (4)	1492 (4)						
300 000-599 999	2181(14)	12 185 (18)	7049 (19)						
600 000-1000 000	4148 (26)	19 323 (29)	9905 (26)						
>1000 000	7096 (45)	27 681 (41)	11 890 (32)						
Missing	1835 (12)	5692 (8)	7227 (19)						
Body mass index (kg/ m <sup>2</sup> )									
<25	7603 (48)	30 902 (46)	16 924 (45)						
≥25	8018 (51)	35 946 (53)	20 301 (54)						
Missing	116(1)	457 (1)	338 (1)						
Smoking status									
Never	8443 (54)	35 418 (53)	18 947 (50)						
Former	6109 (39)	25 651 (38)	14 344 (38)						
Current	890 (5)	4913 (7)	3313 (9)						
Missing	295 (2)	1323 (2)	959 (3)						
Underlying medical									
conditions <sup>e</sup>									
No	11 817 (75)	47 947 (71)	25 654 (68)						
Yes	3777 (24)	18 622 (28)	11 393 (31)						
Missing	143 (1)	736 (1)	516(1)						

407 408 409 410 411 412 413 <sup>a</sup> The SARS-CoV-2 status of the negative participants was obtained from the Norwegian Messaging System for Reporting of Infectious Diseases (MSIS) registry. The SARS-CoV-2-positive status was obtained from the MSIS registry 58% or self-report 42%. Only one SARS-CoV-2-


positive-test was included for each participant. <sup>b</sup> Participants that remained untested for the whole follow-up period

<sup>c</sup> Interquartile range.

<sup>d</sup> Time from the first SARS-CoV-2 positive test or first SARS-CoV-2 negative test to last follow up. For participants remaining untested, time

from baseline to the last follow-up is shown.

414 <sup>e</sup> Chronic heart disease, high blood pressure, chronic lung disease (not asthma), asthma, diabetes, receiving immunodeficiency treatment, cancer 415 (under treatment).



**Figure 1.** The frequencies (moving average and 95% confidence intervals) of symptoms reported before, during and after a positive or negative SARS-CoV-2 test. Participants are grouped by their SARS-CoV-2 status at the end of follow-up. Participants remaining untested for the complete study period (without a test date) are represented with a horizontal (flat) line representing their average (supplementary eMethods 5). The horizontal grey dashed line represents the mean response for untested study participants. The vertical line represents the day of the positive- or negative SARS-CoV-2 test. The figure is based on all completed questionnaires (N=530 200). In each questionnaire, the presence of a symptom the past three weeks was reported by the participant. Note that the 95% confidence interval for the Tested, negative group falls inside the line and it is therefore not visible.

**Table 2.** Odds ratio (OR) estimates and 95% confidence interval (CI) for reporting each symptom at different time-intervals after a positive or negative SARS-CoV-2 test (or inclusion for untested) with symptoms reported 1-3 months after a negative test as reference  $(n = 120\ 605)^*$ .

		Time since test (months) <sup>#</sup>											
		0-1		>1-3		>3-6		>6-12		>12-18		>18	
Symptoms	SARS- CoV-2 status	Yes: n (%)	OR (95% CI)	Yes: n (%)	OR (95% CI)	Yes: n (%)	OR (95% CI)	Yes: n (%)	OR (95% CI)	Yes: n (%)	OR (95% CI)	Yes: n (%)	OR (95% CI)
Memory problems <sup>a</sup>	Untested		0.8 (0.22-2.97)	4 (3.6)	1.01 (0.28-3.65)	22 (2.2)	0.61 (0.36-1.04)	1502 (2.5)	0.72 (0.64-0.81)	58 (4.3)	2.6 (1.81-3.73)	441 (2.4)	1 (0.84-1.19)
	Negative	253 (2.7)	0.8 (0.66-0.96)	604 (3.4)	1 (Ref.)	720 (4.1)	1.33 (1.16-1.54)	836 (4.1)	1.54 (1.34-1.78)	1289 (4.6)	1.49 (1.32-1.69)	417 (6)	1.98 (1.68-2.34)
	Positive	395 (6.8)	3.34 (2.78-4.02)	502 (9.8)	6.18 (5.16-7.42)	481 (12)	9.05 (7.49-10.94)	339 (17.3)	13.3 (10.69-16.55)	101 (13.7)	7.83 (5.68-10.79)	13 (15.5)	9.96 (4.31-23.01)
Concentration problems <sup>a</sup>	Untested		1.46 (0.08-25.56)	7 (6)	0.85 (0.29-2.54)	46 (4.5)	0.71 (0.47-1.06)	2812 (4.7)	0.64 (0.58-0.71)	92 (6.8)	2.34 (1.72-3.19)	698 (3.7)	0.8 (0.69-0.92)
-	Negative	586 (6)	0.95 (0.82-1.09)	1276 (7)	1 (Ref.)	1336 (7.6)	1.17 (1.04-1.3)	1490 (7.2)	1.31 (1.17-1.47)	2179 (7.5)	1.16 (1.05-1.27)	672 (9.6)	1.46 (1.27-1.68)
	Positive	1040 (17.8)	6.05 (5.23-7)	830 (16.2)	5.61 (4.81-6.54)	662 (16.6)	5.71 (4.85-6.73)	423 (21.6)	7.46 (6.11-9.1)	141 (19)	5.27 (3.93-7.06)	17 (20.2)	4.86 (2.13-11.07)
Anosmia and dysgeusia <sup>b</sup>	Untested	6898 (3.5)	1.01 (0.91-1.13)	495 (1.4)	0.65 (0.56-0.74)	1018 (1.3)	0.58 (0.51-0.65)	564 (1)	0.37 (0.33-0.43)	15 (1.1)	0.73 (0.42-1.28)	258 (1.4)	0.69 (0.58-0.81)
	Negative	929 (5.8)	3.27 (2.88-3.71)	575 (2.4)	1 (Ref.)	398 (2)	0.83 (0.72-0.96)	459 (2.2)	0.96 (0.83-1.11)	704 (2.4)	1.13 (0.99-1.28)	234 (3.4)	1.31 (1.09-1.57)
	Positive	2004 (33.8)	66.22 (57.75-75.93)	587 (11.4)	9.65 (8.31-11.21)	310 (7.7)	5.22 (4.38-6.22)	248 (12.6)	8.88 (7.24-10.88)	80 (10.8)	5.47 (4-7.48)	13 (15.5)	5.28 (2.44-11.43)

#### Table 2 cont.

		Time since test (months) <sup>#</sup>											
	SARS- CoV-2 status	0-1		>1-3		>3-6		>6-12		>12-18		>18	
Symptoms		Yes: n (%)	OR (95% CI)	Yes: n (%)	OR (95% CI)	Yes: n (%)	OR (95% CI)	Yes: n (%)	OR (95% CI)	Yes: n (%)	OR (95% CI)	Yes: n (%)	OR (95% CI)
Dyspnoea <sup>b</sup>	Untested	17386 (8.7)	0.98 (0.91-1.05)	1445 (4.2)	0.58 (0.53-0.64)	2672 (3.5)	0.48 (0.44-0.51)	2152 (3.3)	0.48 (0.44-0.52)	91 (6.8)	1.62 (1.22-2.14)	664 (3.5)	0.58 (0.52-0.65)
	Negative	2212 (13.8)	3.04 (2.78-3.32)	1761 (7.2)	1 (Ref.)	1348 (6.9)	0.99 (0.9-1.08)	1380 (6.7)	0.95 (0.87-1.05)	1858 (6.4)	0.99 (0.91-1.07)	625 (9)	0.97 (0.86-1.09)
	Positive	1765 (29.7)	14.14 (12.69-15.76)	769 (14.9)	4.07 (3.6-4.6)	449 (11.1)	2.44 (2.12-2.81)	247 (12.6)	2.66 (2.2-3.21)	82 (11.1)	2.02 (1.49-2.73)	10 (11.9)	2.03 (0.9-4.59)
Fatigue <sup>b</sup>	Untested	34532 (17.4)	0.51 (0.49-0.54)	3779 (11)	0.47 (0.44-0.49)	8332 (10.9)	0.43 (0.41-0.45)	7667 (11.7)	0.57 (0.54-0.6)	227 (16.9)	1.43 (1.19-1.73)	1982 (10.5)	0.63 (0.59-0.68)
	Negative	5617 (35)	2.92 (2.76-3.1)	5245 (21.5)	1 (Ref.)	4306 (22)	1.08 (1.02-1.15)	4359 (21)	1.14 (1.08-1.21)	6578 (22.8)	1.23 (1.17-1.3)	1953 (28)	1.44 (1.33-1.55)
	Positive	4236 (71.4)	27.63 (25.25-30.23)	1735 (33.5)	2.86 (2.62-3.12)	1182 (29.3)	2.02 (1.83-2.23)	647 (32.9)	2.47 (2.16-2.82)	218 (29.5)	1.78 (1.44-2.2)	26 (31)	1.3 (0.72-2.36)
Self-assessed worsening of	Untested	27 (13.3)	0.5 (0.3-0.82)	1625 (11.9)	0.49 (0.45-0.53)	8070 (10.6)	0.42 (0.39-0.44)	8652 (13.3)	0.66 (0.62-0.69)	107 (10.7)	0.52 (0.4-0.66)	2137 (11.5)	0.55 (0.51-0.59)
overall health <sup>c</sup>	Negative	2308 (16.5)	0.84 (0.78-0.9)	4461 (18.7)	1 (Ref.)	3740 (19.4)	1.06 (1-1.13)	3811 (18.8)	1.02 (0.96-1.09)	5193 (18.1)	1 (0.95-1.06)	1432 (20.7)	1.01 (0.93-1.1)
	Positive	1717 (29.7)	2.38 (2.18-2.59)	1537 (30.6)	2.61 (2.38-2.85)	1041 (28.0)	2.32 (2.1-2.57)	618 (37.1)	3.63 (3.15-4.19)	238 (36.2)	3.44 (2.77-4.26)	30 (40.0)	3.77 (2.05-6.94)

<sup>\*</sup> Adjusted for age (10-years categories), gender (men, women) body mass index (<25 kg/ m2, ≥25 kg/ m2), income level per household (< 299 999, 300 000-599 999, 600 000-1000 000, >1000 000 NOK, missing), smoking status (never, former, current, missing), underlying medical condition (no, yes, missing) and symptom status at baseline (no, yes, missing).

<sup>#</sup>For the untested, time since baseline was used in place of time since a positive- or negative SARS-CoV-2 test.

<sup>a</sup>n = 200 778 questionnaires, 120 605 participants

<sup>b</sup>n = 530 200 questionnaires, 120 605 participants

<sup>c</sup>n = 304 958 questionnaires, 120 605 participants

# Acknowledgments

We thank Dr Fridtjof Lund Johansen at Oslo University Hospital for organizing and carrying out the serological analyses.

### **Author contributions**

Merete Ellingjord-Dale, Anders B. Nygaard, and Arne Søraas had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Merete Ellingjord-Dale and Anders B. Nygaard contributed equally as co-first authors.

Conceptualization: Arne Søraas and Karl Trygve Kalleberg.

Design of study and analyses: Merete Ellingjord-Dale, Anders B. Nygaard, Karl Trygve Kalleberg, John Arne Dahl, Sonja H. Brunvoll, Nathalie C. Støer, Linda Geng, Giske Ursin and Arne Søraas.

Acquisition, analysis, or interpretation of data: all authors.

Data curation and statistical analysis: Merete Ellingjord-Dale, Anders B. Nygaard, Ragnhild Bø, Nils Inge Landrø and Arne Søraas.

Drafting of the manuscript: Merete Ellingjord-Dale, Anders B. Nygaard, Sonja H. Brunvoll, Nathalie C. Støer, Giske Ursin, and Arne Søraas.

Critical revision of the manuscript for important intellectual content: all authors.

Administrative and technical support: Mette S. Istre.

Supervision: Giske Ursin, Nathalie C. Støer and Arne Søraas.

Final approval of the manuscript and work: all authors.

#### **Conflict of interest disclosures**

All authors declared no potential conflicts of interest. However, Karl Trygve Kalleberg and Arne Søraas are founders and shareholders of the company Age Labs AS which develops epigenetic tests, including one for COVID-19 severity.

### Funding

This work was funded by the Research Council of Norway (no: 324274) and Southern and Eastern Norway Regional Health Authority (internal funding). The funder had no role in the conduction, collection of data or interpretation of results.

#### **Additional contributions**

The authors would like to thank all the participants in the study.

#### **Transparancy statement**

The lead authors (MED and ABN) affirm that this manuscript is an honest, accurate, and transparent account of the trial being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned, and registered have been explained.

#### Data availability statement

Individual level data from the study for the purposes outlined in the consent form can be shared with other researchers in a timely fashion. The data are regulated under the European GDPR regulative and sharing of data must be approved by the Data Protection Officer at Oslo

University Hospital. Data will be made available for researchers whose proposed use of the data has been approved.

# References

1. WHO. WHO Coronavirus (COVID-19) Dashboard. 2021. <u>https://covid19.who.int/</u> (accessed April 6 2023).

 Ballering AV, van Zon SKR, olde Hartman TC, Rosmalen JGM. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. *The Lancet* 2022; **400**(10350): 452-61.
 Rando HM, Bennett TD, Byrd JB, et al. Challenges in defining Long COVID: Striking differences

across literature, Electronic Health Records, and patient-reported information. *medRxiv* 2021.

4. Fernandez-de-Las-Penas C, Palacios-Cena D, Gomez-Mayordomo V, Cuadrado ML, Florencio LL. Defining Post-COVID Symptoms (Post-Acute COVID, Long COVID, Persistent Post-COVID): An Integrative Classification. *Int J Environ Res Public Health* 2021; **18**(5).

5. Alwan NA, Johnson L. Defining long COVID: Going back to the start. *Med (N Y)* 2021; **2**(5): 501-4.

6. Sivan M, Taylor S. NICE guideline on long covid. *Bmj* 2020; **371**: m4938.

7. WHO. World Health Organization. Post COVID-19 condition (Long COVID). 2021.

https://www.who.int/srilanka/news/detail/16-10-2021-post-covid-19-condition (accessed April 14 2023).

8. COVID.gov. Department of Health and Human Services. What is Long COVID? <u>https://www.covid.gov/longcovid/definitions</u> (accessed April 14 2023).

9. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. *Nature Reviews Microbiology* 2023.

10. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine* 2021; **38**: 101019.

11. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More Than 50 Long-Term Effects of COVID-19: A Systematic Review and Meta-Analysis. *Res Sq* 2021.

12. Hampshire A, Trender W, Chamberlain S, et al. Cognitive deficits in people who have recovered from COVID-19 relative to controls: An N=84,285 online study. medRxiv; 2020.

13. Soraas A, Bo R, Kalleberg KT, Stoer NC, Ellingjord-Dale M, Landro NI. Self-reported Memory Problems 8 Months After COVID-19 Infection. *JAMA Netw Open* 2021; **4**(7): e2118717.

14. Becker JH, Lin JJ, Doernberg M, et al. Assessment of Cognitive Function in Patients After COVID-19 Infection. *JAMA Netw Open* 2021; **4**(10): e2130645.

15. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019: A Review. *JAMA* 2020; **324**(8): 782-93.

Prescott HC, Angus DC. Enhancing Recovery From Sepsis: A Review. *JAMA* 2018; **319**(1): 62-75.
 Invernizzi A, Renzetti S, van Thriel C, et al. Covid-19 related cognitive, structural and functional

brain changes among Italian adolescents and young adults: a multimodal longitudinal case-control study. *medRxiv* 2023: 2023.07. 19.23292909.

18. Vakani K, Ratto M, Sandford-James A, Antonova E, Kumari V. COVID-19 and Cognitive Function: Evidence for Increased Processing Speed Variability in COVID-19 Survivors and Multifaceted Impairment with Long-COVID Symptoms. *European Psychiatry* 2023: 1-34.

19. Kopańska M, Ochojska D, Muchacka R, Dejnowicz-Velitchkov A, Banaś-Ząbczyk A, Szczygielski J. Comparison of qeeg findings before and after onset of post-COVID-19 brain fog symptoms. *Sensors* 2022; **22**(17): 6606.

20. Ballering AV, van Zon SK, Olde Hartman TC, Rosmalen JG. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. *The Lancet* 2022; **400**(10350): 452-61.

21. Quan M, Wang X, Gong M, Wang Q, Li Y, Jia J. Post-COVID cognitive dysfunction: current status and research recommendations for high risk population. *The Lancet Regional Health–Western Pacific* 2023; **38**.

22. Lapin B, Katzan IL. Health-Related Quality of Life Mildly Affected Following COVID-19: a Retrospective Pre-post Cohort Study with a Propensity Score-Matched Control Group. *J Gen Intern Med* 2022; **37**(4): 862-9.

23. Durstenfeld MS, Peluso MJ, Peyser ND, et al. Factors Associated With Long COVID Symptoms in an Online Cohort Study. *Open Forum Infect Dis* 2023; **10**(2): ofad047.

24. ISARIC. COVID-19 Long Term Protocol. Tier 1 Initial Follow up Survey. 2020.

https://isaric.org/wp-content/uploads/2020/12/Tier-1-Initial-Follow\_up\_survey.pdf (accessed April 14 2023).

25. RAND. RAND Health Care. 36-Item Short Form Survey Instrument (SF-36).

https://www.rand.org/health-care/surveys\_tools/mos/36-item-short-form/survey-instrument.html (accessed April 14 2023).

26. Roth R, Isquith P, Gioia G. Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A); 2005.

27. Royle J, Lincoln NB. The Everyday Memory Questionnaire-revised: development of a 13-item scale. *Disabil Rehabil* 2008; **30**(2): 114-21.

28. WHO. World Health Organization. Post COVID-19 condition (Long COVID). 2022.

https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition (accessed April 14 2023).

29. Corbett A, Williams G, Creese B, et al. Cognitive decline in older adults in the UK during and after the COVID-19 pandemic: a longitudinal analysis of PROTECT study data. *The Lancet Healthy Longevity* 2023; **4**(11): e591-e9.

30. Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. *Nature* 2022; **604**(7907): 697-707.

31. Lambrecq V, Hanin A, Munoz-Musat E, et al. Association of Clinical, Biological, and Brain Magnetic Resonance Imaging Findings With Electroencephalographic Findings for Patients With COVID-19. JAMA Netw Open 2021; **4**(3): e211489.

32. Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. *Nature* 2022; **612**(7941): 758-63.

33. Gidon A, Zolnik TA, Fidzinski P, et al. Dendritic action potentials and computation in human layer 2/3 cortical neurons. *Science* 2020; **367**(6473): 83-7.

34. Velmeshev D, Schirmer L, Jung D, et al. Single-cell genomics identifies cell type-specific molecular changes in autism. *Science* 2019; **364**(6441): 685-9.

35. Beck JW, Flow A. The effects of contracting Covid-19 on cognitive failures at work: implications for task performance and turnover intentions. *Scientific Reports* 2022; **12**(1): 8826.

36. Reiken S, Sittenfeld L, Dridi H, Liu Y, Liu X, Marks AR. Alzheimer's-like signaling in brains of COVID-19 patients. *Alzheimer's & Dementia* 2022; **18**(5): 955-65.

37. Logie RH, Camos V, Cowan N. 1C1The State of the Science of Working Memory: An Introduction. In: Logie R, Camos V, Cowan N, eds. Working Memory: The state of the science: Oxford University Press; 2020: 0.

38. Sheehy LM. Considerations for Postacute Rehabilitation for Survivors of COVID-19. *JMIR Public Health Surveill* 2020; **6**(2): e19462.

39. Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. *Nature Medicine* 2023.

40. Peter RS, Nieters A, Kräusslich H-G, et al. Post-acute sequelae of covid-19 six to 12 months after infection: population based study. *BMJ* 2022; **379**: e071050.